478 related articles for article (PubMed ID: 26220290)
1. Comparative efficacy of experimental inactivated and live-attenuated chimeric porcine circovirus (PCV) 1-2b vaccines derived from PCV1 and PCV2b isolates originated in China.
Li J; Yu T; Wang X; Zhou J; Gao R; Zhang F; Gao X; Gao S; Liu X
Virol J; 2015 Jul; 12():113. PubMed ID: 26220290
[TBL] [Abstract][Full Text] [Related]
2. A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection.
Opriessnig T; O'Neill K; Gerber PF; de Castro AM; Gimenéz-Lirola LG; Beach NM; Zhou L; Meng XJ; Wang C; Halbur PG
Vaccine; 2013 Jan; 31(3):487-94. PubMed ID: 23174198
[TBL] [Abstract][Full Text] [Related]
3. Novel chimeric porcine circovirus (PCV) with the capsid gene of the emerging PCV2b subtype cloned in the genomic backbone of the non-pathogenic PCV1 is attenuated in vivo and induces protective and cross-protective immunity against PCV2b and PCV2a subtypes in pigs.
Beach NM; Ramamoorthy S; Opriessnig T; Wu SQ; Meng XJ
Vaccine; 2010 Dec; 29(2):221-32. PubMed ID: 21044670
[TBL] [Abstract][Full Text] [Related]
4. A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs.
Fenaux M; Opriessnig T; Halbur PG; Elvinger F; Meng XJ
J Virol; 2004 Jun; 78(12):6297-303. PubMed ID: 15163723
[TBL] [Abstract][Full Text] [Related]
5. Inactivated chimeric porcine circovirus (PCV) 1-2 vaccines based on genotypes 2b and 2d exhibit similar immunological effectiveness in protecting pigs against challenge with PCV2b strain 0233.
Li J; Yu T; Zhang F; Wang X; Zhou J; Gao X; Gao S; Liu X
Arch Virol; 2017 Jan; 162(1):235-246. PubMed ID: 27722993
[TBL] [Abstract][Full Text] [Related]
6. An experimental live chimeric porcine circovirus 1-2a vaccine decreases porcine circovirus 2b viremia when administered intramuscularly or orally in a porcine circovirus 2b and porcine reproductive and respiratory syndrome virus dual-challenge model.
Opriessnig T; Gomes-Neto JC; Hemann M; Shen HG; Beach NM; Huang Y; Halbur PG; Meng XJ
Microbiol Immunol; 2011 Dec; 55(12):863-73. PubMed ID: 21951266
[TBL] [Abstract][Full Text] [Related]
7. A candidate inactivated chimeric vaccine PCV1-2 constructed based on PCV1 and PCV2 isolates originating in China and its evaluation in conventional pigs in regard to protective efficacy against PCV2 infection.
Xujie L; Xiaobo W; Yi S; Jing F; Song G; Xiufan L
Microbiol Immunol; 2011 Apr; 55(4):254-66. PubMed ID: 21244470
[TBL] [Abstract][Full Text] [Related]
8. A live-attenuated chimeric porcine circovirus type 2 (PCV2) vaccine is transmitted to contact pigs but is not upregulated by concurrent infection with porcine parvovirus (PPV) and porcine reproductive and respiratory syndrome virus (PRRSV) and is efficacious in a PCV2b-PRRSV-PPV challenge model.
Opriessnig T; Shen HG; Pal N; Ramamoorthy S; Huang YW; Lager KM; Beach NM; Halbur PG; Meng XJ
Clin Vaccine Immunol; 2011 Aug; 18(8):1261-8. PubMed ID: 21653745
[TBL] [Abstract][Full Text] [Related]
9. Colonisation of mice and pigs by a chimeric porcine circovirus 1-2 prototype vaccine strain and a PCV2 isolate originating in China and their induction of cytokines.
Cui X; Wang X; Gao Q; Liu X; Kai Y; Chen C; Gao S
J Virol Methods; 2020 Sep; 283():113905. PubMed ID: 32502500
[TBL] [Abstract][Full Text] [Related]
10. Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge.
Seo HW; Oh Y; Han K; Park C; Chae C
BMC Vet Res; 2012 Oct; 8():194. PubMed ID: 23078878
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with inactivated or live-attenuated chimeric PCV1-2 results in decreased viremia in challenge-exposed pigs and may reduce transmission of PCV2.
Hemann M; Beach NM; Meng XJ; Halbur PG; Opriessnig T
Vet Microbiol; 2012 Jul; 158(1-2):180-6. PubMed ID: 22341313
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Efficacy and Cross-Protective Immunity of Live-Attenuated Chimeric PCV1-2b Vaccine Against PCV2b and PCV2d Subtype Challenge in Pigs.
Huan C; Fan M; Cheng Q; Wang X; Gao Q; Wang W; Gao S; Liu X
Front Microbiol; 2018; 9():455. PubMed ID: 29599761
[TBL] [Abstract][Full Text] [Related]
13. A chimeric virus created by DNA shuffling of the capsid genes of different subtypes of porcine circovirus type 2 (PCV2) in the backbone of the non-pathogenic PCV1 induces protective immunity against the predominant PCV2b and the emerging PCV2d in pigs.
Matzinger SR; Opriessnig T; Xiao CT; Catanzaro N; Beach NM; Slade DE; Nitzel GP; Meng XJ
Virology; 2016 Nov; 498():82-93. PubMed ID: 27564544
[TBL] [Abstract][Full Text] [Related]
14. Expression of antigenic epitopes of porcine reproductive and respiratory syndrome virus (PRRSV) in a modified live-attenuated porcine circovirus type 2 (PCV2) vaccine virus (PCV1-2a) as a potential bivalent vaccine against both PCV2 and PRRSV.
Piñeyro PE; Kenney SP; Giménez-Lirola LG; Heffron CL; Matzinger SR; Opriessnig T; Meng XJ
Virus Res; 2015 Dec; 210():154-64. PubMed ID: 26239318
[TBL] [Abstract][Full Text] [Related]
15. A live-attenuated and an inactivated chimeric porcine circovirus (PCV)1-2 vaccine are both effective at inducing a humoral immune response and reducing PCV2 viremia and intrauterine infection in female swine of breeding age.
Hemann M; Beach NM; Meng XJ; Wang C; Halbur PG; Opriessnig T
Can J Vet Res; 2014 Jan; 78(1):8-16. PubMed ID: 24396175
[TBL] [Abstract][Full Text] [Related]
16. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions.
Opriessnig T; Xiao CT; Halbur PG; Gerber PF; Matzinger SR; Meng XJ
Vaccine; 2017 Jan; 35(2):248-254. PubMed ID: 27919634
[TBL] [Abstract][Full Text] [Related]
17. Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2.
Opriessnig T; Gerber PF; Xiao CT; Halbur PG; Matzinger SR; Meng XJ
Vaccine; 2014 Jul; 32(34):4342-8. PubMed ID: 24929119
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and phylogenetic analysis of the current porcine circovirus 2 genotypes after implementation of widespread vaccination programmes in the USA.
Shen HG; Halbur PG; Opriessnig T
J Gen Virol; 2012 Jun; 93(Pt 6):1345-1355. PubMed ID: 22398315
[TBL] [Abstract][Full Text] [Related]
19. A commercial PCV2a-based vaccine is effective in protection from experimental challenge of PCV2 mutant with two amino acids elongation in capsid protein.
Guo LJ; Fu YJ; Huang LP; Wang YP; Wei YW; Wu HL; Liu CM
Vaccine; 2015 Jul; 33(31):3752-7. PubMed ID: 26051516
[TBL] [Abstract][Full Text] [Related]
20. A Porcine circovirus type 2b (PCV2b)-based experimental vaccine is effective in the PCV2b-Mycoplasma hyopneumoniae coinfection pig model.
Opriessnig T; Castro AMMG; Karuppanan AK; Gauger PC; Halbur PG; Matzinger SR; Meng XJ
Vaccine; 2019 Oct; 37(44):6688-6695. PubMed ID: 31537445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
